Trending NewsTrending NewsNYSE:NVO Novo Nordisk A/S (NVO) Stock Price, News & Analysis $44.53 -0.54 (-1.19%) As of 01:52 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Novo Nordisk A/S Stock (NYSE:NVO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Novo Nordisk A/S alerts:Sign Up Key Stats Today's Range$43.74▼$44.4250-Day Range$35.28▼$47.1352-Week Range$35.12▼$81.44Volume7.04 million shsAverage Volume21.30 million shsMarket Capitalization$198.84 billionP/E Ratio10.44Dividend Yield3.93%Price Target$65.56Consensus RatingHold Company Overview Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support. The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments. Novo Nordisk has been a major commercial and scientific driver of GLP-1 receptor agonists, marketed under well-known brand names for glucose control and weight management. In addition to diabetes and obesity medicines, the company supplies treatments for haemophilia and other rare bleeding disorders, as well as growth disorders and hormone replacement therapies. Its offerings combine pharmaceuticals with delivery devices and patient services aimed at improving adherence and outcomes. Research and development are central to Novo Nordisk’s strategy, with continued investment in next-generation medicines for metabolic, cardiovascular and rare diseases. The company operates global manufacturing and distribution networks and markets its products broadly, with significant commercial operations in the United States, Europe and other international markets. Novo Nordisk also engages in partnerships and licensing arrangements with academic institutions, biotechnology firms and healthcare organizations to support innovation and expand access to therapies. Leadership is focused on long-term innovation and patient-centric care; the company is led by President and CEO Lars Fruergaard Jørgensen. Novo Nordisk positions itself as a specialist pharmaceutical company with a mission to improve the lives of people with chronic conditions through medical innovation, comprehensive treatment solutions and support services for patients and healthcare providers.AI Generated. May Contain Errors. Read More Novo Nordisk A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks95th Percentile Overall ScoreNVO MarketRank™: Novo Nordisk A/S scored higher than 95% of companies evaluated by MarketBeat, and ranked 28th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingNovo Nordisk A/S has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on no strong buy ratings, 4 buy ratings, 18 hold ratings, and 1 sell rating.Upside PotentialNovo Nordisk A/S has a consensus price target of $65.56, representing about 48.7% upside from its current price of $44.10.Amount of Analyst CoverageNovo Nordisk A/S has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Novo Nordisk A/S's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-0.58% Earnings GrowthEarnings for Novo Nordisk A/S are expected to decrease by -0.58% in the coming year, from $3.47 to $3.45 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novo Nordisk A/S is 10.36, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.52.Price to Earnings Ratio vs. SectorThe P/E ratio of Novo Nordisk A/S is 10.36, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.81.Price to Earnings Growth RatioNovo Nordisk A/S has a PEG Ratio of 3.94. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioNovo Nordisk A/S has a P/B Ratio of 6.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Novo Nordisk A/S's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.31% of the float of Novo Nordisk A/S has been sold short.Short Interest Ratio / Days to CoverNovo Nordisk A/S has a short interest ratio ("days to cover") of 0.78, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Novo Nordisk A/S has recently decreased by 17.77%, indicating that investor sentiment is improving significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend LeadershipNovo Nordisk A/S is a leading dividend payer. It pays a dividend yield of 3.95%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthNovo Nordisk A/S does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Novo Nordisk A/S is 41.08%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 50.72% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.Read more about Novo Nordisk A/S's dividend. News and Social Media4.3 / 5News Sentiment0.85 News SentimentNovo Nordisk A/S has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 49 news articles for Novo Nordisk A/S this week, compared to 11 articles on an average week.Search Interest177 people have searched for NVO on MarketBeat in the last 30 days. This is an increase of 54% compared to the previous 30 days.MarketBeat Follows54 people have added Novo Nordisk A/S to their MarketBeat watchlist in the last 30 days. This is an increase of 135% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Novo Nordisk A/S insiders have not sold or bought any company stock.Percentage Held by Insiders0.07% of the stock of Novo Nordisk A/S is held by insiders.Percentage Held by Institutions11.54% of the stock of Novo Nordisk A/S is held by institutions.Read more about Novo Nordisk A/S's insider trading history. Receive NVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NVO Stock News HeadlinesThe Silver Lining of Last Week's Hims & Hers Earnings Miss (NVO)Hims & Hers plunged 23% after a major Q1 earnings miss, but long-term growth stays intact via its Novo Nordisk GLP-1 partnership and a late 2026 expansion.2 hours ago | marketbeat.comCould Viking Therapeutics Be the Next Eli Lilly?4 hours ago | fool.com$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…May 21 at 1:00 AM | Paradigm Press (Ad)Focus: Lower cost Novo, Lilly weight-loss pills draw patients from compounded drugs, doctors sayMay 21 at 6:02 AM | reuters.comBest Weight Loss Drug Stocks to Buy in 2026May 20 at 11:15 PM | fool.comFrom Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook (NVO)Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of demand.May 20 at 2:55 PM | marketbeat.com2 Ways to Play the Big Pharma Patent Cliff (NVO)With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.May 14, 2026 | marketbeat.comHims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery? (NVO)Hims & Hers Health posted a Q1 FY2026 double miss, with an EPS loss of $0.40 and revenue of $608.1 million, sending shares down more than 12% after hours.May 12, 2026 | marketbeat.comSee More Headlines NVO Stock Analysis - Frequently Asked Questions How have NVO shares performed this year? Novo Nordisk A/S's stock was trading at $50.88 at the start of the year. Since then, NVO stock has decreased by 13.3% and is now trading at $44.1340. How were Novo Nordisk A/S's earnings last quarter? Novo Nordisk A/S (NYSE:NVO) announced its quarterly earnings data on Tuesday, March, 31st. The company reported $1.03 EPS for the quarter. The company had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a trailing twelve-month return on equity of 63.31%. When did Novo Nordisk A/S's stock split? Novo Nordisk A/S shares split before market open on Wednesday, September 20th 2023.The 2-1 split was announced on Wednesday, September 20th 2023. The newly created shares were distributed to shareholders after the closing bell on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. Does Novo Nordisk A/S have any subsidiaries? Novo Nordisk A/S subsidiaries include these companies: Dicerna Pharmaceuticals, Emisphere Technologies, Corvidia Therapeutics, Ziylo, Calibrium, MB2 LLC, Xellia Pharmaceuticals, and others. Who are Novo Nordisk A/S's major shareholders? Novo Nordisk A/S's top institutional shareholders include Bank of America Corp DE (0.24%), Arrowstreet Capital Limited Partnership (0.18%), Royal Bank of Canada (0.10%) and Renaissance Technologies LLC (0.08%). View institutional ownership trends. How do I buy shares of Novo Nordisk A/S? Shares of NVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Novo Nordisk A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novo Nordisk A/S investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), ServiceNow (NOW), Advanced Micro Devices (AMD), Salesforce (CRM) and Eli Lilly and Company (LLY). Company Calendar Record date for 4/8 Dividend3/30/2026Ex-Dividend for 4/8 Dividend3/30/2026Last Earnings3/31/2026Dividend Payable4/08/2026Today5/21/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 10 days, NVO's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Large Cap Pharma Sub-IndustryPharmaceutical Products Current SymbolNYSE:NVO CIK353278 Webwww.novonordisk.com Phone(454) 444-8888Fax45-4449-0555Employees69,505Year Founded1923Price Target and Rating Average Price Target for Novo Nordisk A/S$65.56 High Price Target$175.00 Low Price Target$40.00 Potential Upside/Downside+47.3%Consensus RatingHold Rating Score (0-4)2.13 Research Coverage23 Analysts Profitability EPS (Trailing Twelve Months)$4.26 Trailing P/E Ratio10.44 Forward P/E Ratio12.83 P/E Growth3.94Net Income$15.51 billion Net Margins37.23% Pretax Margin47.66% Return on Equity63.31% Return on Assets22.19% Debt Debt-to-Equity Ratio0.59 Current Ratio0.79 Quick Ratio0.56 Sales & Book Value Annual Sales$46.80 billion Price / Sales4.25 Cash Flow$4.71 per share Price / Cash Flow9.45 Book Value$7.12 per share Price / Book6.25Miscellaneous Outstanding Shares4,465,000,000Free Float4,461,875,000Market Cap$198.76 billion OptionableOptionable Beta0.77 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NYSE:NVO) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novo Nordisk A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Novo Nordisk A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
